Cargando…
Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response?
The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 1...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139159/ https://www.ncbi.nlm.nih.gov/pubmed/37108654 http://dx.doi.org/10.3390/ijms24087491 |
_version_ | 1785032879377481728 |
---|---|
author | Asero, Riccardo Ferrucci, Silvia Mariel Calzari, Paolo Consonni, Dario Cugno, Massimo |
author_facet | Asero, Riccardo Ferrucci, Silvia Mariel Calzari, Paolo Consonni, Dario Cugno, Massimo |
author_sort | Asero, Riccardo |
collection | PubMed |
description | The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 123/262; mean age 49.5 years; range 12–87 years) with severe CSU were studied. Total IgE levels and thyroid autoimmunity (levels of anti-thyroid peroxidase [TPO] IgG) were measured before omalizumab treatment. Based on the clinical response, patients were divided into early (ER), late (LR), partial (PR) and non (NR) responders to omalizumab. Thyroid autoimmunity was detected in 92/385 (24%) patients. Altogether, 52%, 22%, 16% and 10% of patients were ER, LR, PR and NR to omalizumab, respectively. Response to omalizumab was not associated with thyroid autoimmunity (p = 0.77). Conversely, we found a strongly positive association between IgE levels and omalizumab response (p < 0.0001); this association was largely driven by early response (OR = 5.46; 95% CI: 2.23–13.3). Moreover, the predicted probabilities of early response strongly increased with increasing IgE levels. Thyroid autoimmunity alone cannot be used as a clinical predictor of omalizumab response. Total IgE levels remain the only and most reliable prognostic marker for omalizumab response in patients with severe CSU. |
format | Online Article Text |
id | pubmed-10139159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101391592023-04-28 Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? Asero, Riccardo Ferrucci, Silvia Mariel Calzari, Paolo Consonni, Dario Cugno, Massimo Int J Mol Sci Communication The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear. Three hundred and eighty-five patients (M/F 123/262; mean age 49.5 years; range 12–87 years) with severe CSU were studied. Total IgE levels and thyroid autoimmunity (levels of anti-thyroid peroxidase [TPO] IgG) were measured before omalizumab treatment. Based on the clinical response, patients were divided into early (ER), late (LR), partial (PR) and non (NR) responders to omalizumab. Thyroid autoimmunity was detected in 92/385 (24%) patients. Altogether, 52%, 22%, 16% and 10% of patients were ER, LR, PR and NR to omalizumab, respectively. Response to omalizumab was not associated with thyroid autoimmunity (p = 0.77). Conversely, we found a strongly positive association between IgE levels and omalizumab response (p < 0.0001); this association was largely driven by early response (OR = 5.46; 95% CI: 2.23–13.3). Moreover, the predicted probabilities of early response strongly increased with increasing IgE levels. Thyroid autoimmunity alone cannot be used as a clinical predictor of omalizumab response. Total IgE levels remain the only and most reliable prognostic marker for omalizumab response in patients with severe CSU. MDPI 2023-04-19 /pmc/articles/PMC10139159/ /pubmed/37108654 http://dx.doi.org/10.3390/ijms24087491 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Asero, Riccardo Ferrucci, Silvia Mariel Calzari, Paolo Consonni, Dario Cugno, Massimo Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title | Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title_full | Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title_fullStr | Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title_full_unstemmed | Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title_short | Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? |
title_sort | thyroid autoimmunity in csu: a potential marker of omalizumab response? |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139159/ https://www.ncbi.nlm.nih.gov/pubmed/37108654 http://dx.doi.org/10.3390/ijms24087491 |
work_keys_str_mv | AT aseroriccardo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse AT ferruccisilviamariel thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse AT calzaripaolo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse AT consonnidario thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse AT cugnomassimo thyroidautoimmunityincsuapotentialmarkerofomalizumabresponse |